factor for MACE (OR¼2.4; p¼0.04), and death (OR¼6.8; p¼0.001). Upon multivariate logistic regression adjusting for CKD, DEB/DES length, and focal ISR, DEB was not associated with MACE (OR¼0.9; p¼0.71) or death (OR¼1.7; p¼0.44). Conclusions: Chronic kidney disease is an independent predictor of adverse outcomes following percutaneous treatment of ISR. When adjusted for confounders, DEB and DES are associated with similar outcomes in this setting.
Background: Stent fracture (SF) is one of the complications after percutaneous coronary intervention (PCI), although it is not often. To date many data on first generation drug-eluting stent (DES) fracture were published. However study on second generation DES fracture is rare. The aim of this study was to assess the predictors of second generation DES fracture. Methods: From March 2010 to August 2012, a total of 1032 patients with 1283 lesions who underwent successful implantation with second generation DES at Inje University Haeundae Paik Hospital were followed prospectively. Among them, 369 patients (35.7%) with 476 (37.1%) lesions who underwent follow-up coronary angiography (CAG) 6 to 12 months after initial procedure, irrespective of clinical symptoms, were performed. Results: SF was identified in 45 of 1032 patients (4.36%) and 51 of 1283 lesions (3.82%). The patients were divided into SF group and non-SF group. The most prevalent vessel of SF was the left anterior descending artery (24 lesions, 47.1%), followed by the right coronary artery (16 lesions, 31.4%). Most lesions were classified as type B2 (15 lesions, 29.4%) or type C (22 lesions, 43.2%). All implanted stents were the second generation DES such as everolimus-eluting stents (17 stents, 33.3%), zotarolimus-eluting stents (12 stents, 23.5%) and biolimus-eluting stents (10 stents, 19.7%). Compared with non-SF group, SF group was more likely to have stent overlap (52.4% vs. 22.4%; p<0.001) and peri-procedural myocardial infarction (32.6% vs. 12.1%; p<0.001). On multivariate logistic regression analysis, stent overlap (odds ratio 3.45, 95% confidence interval 1.66-7.17, p<0.001), Biolimuseluting stents (odds ratio 6.17, 95% confidence interval 2.19, p<0.001), stent length (odds ratio 1.07, 95% confidence interval 1.02-1.13, p¼0.009), and peri-procedural MI (odds ratio 3.14, 95% confidence interval 1.36-7.23, p ¼0.007), were identified as independent predictors for fracture of second generation stent. Conclusions: The incidence of stent fracture in the second generation DES was 3.82%. The biolimus-eluting stent, overlapping stent, peri-procedural MI, and long stent length are significant determinants of stent fracture in the second generation.
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Multiple Predictors of In-Stent Restenosis with Clinical Presentation of Acute Coronary Syndrome After Drug-Eluting Stent Implantation Soon Jun Hong 1 , Chul-Min Ahn 2 , Do-Sun Lim 1 , Jae Hyoung Park 1 , Cheol Woong Yu 3 1 Korea University Anam Hospital, Seoul, Korea, Republic of, 2 Korea University, Seoul, Korea, Republic of, 3 Sejong General Hospital, Bucheon, Kyeong-gi Background: Although in-stent restenosis (ISR) after drug-eluting stent (DES) is perceived to be a benign phenomenon, some patients with ISR showed clinical presentation of acute coronary syndrome (ACS). We sought to identify parameters influencing the likelihood of restenosis with clinical presentation of ACS after DES implantation. Methods: Stented patients (n¼3,817) with DESs were retrospectively reviewed for inclusion in the study from the Korea University PCI Database Registry. From this database, age and sex-matched 302 patients (7.9%) with ISR were assigned to either the Stable ISR group (n¼156) or the ACS ISR group (n¼146). Predictors of coronary restenosis with clinical presentation of ACS were identified with Cox regression analyses. Results: The rate of risk factors such smoking, hypertension, and diabetes were similar between the 2 groups; moreover, the use of medications at baseline did not differ significantly between the 2 groups. More patients in the ACS ISR group showed two vessel diseases (n¼70 [47.9%] vs. n¼44 [28.2%], P¼0.028, respectively). No significant differences in ISR pattern were noted between the 2 groups during the follow-up angiogram. Follow-up MMP-2 level was significantly higher in the ACS ISR group when compared to the Stable ISR group (66,639+/-12,519 vs. 57,386+/-2,423, P¼0.011, respectively). Age (Hazard ratio [HR], 1.13; 95% confidence interval [CI], 1.02 to 1.26; P¼0.024), diabetes (HR, 6.80; 95% CI, 1.16 to 39.9; P¼0.034), the use of aspirin (HR, 0.005; 95% CI, 0.001 to 0.760; P¼0.039), clopidogrel (HR, 0.010; 95% CI, 0.001 to 0.162; P¼0.001), ACE inhibitor (HR, 0.210; 95% CI, 0.003 to 0.515; P<0.001), the use of first generation DES (HR, 1.130; 95% CI, 1.030 to 1.260; P¼0.001), and MMP-2 level (HR, 1.120; 95% CI, 1.001 to 1.190; P¼0.004) during follow-up were significant predictors of ISR with clinical presentation of ACS during the 3-year follow-up. Conclusions: In the era of DES, older age, diabetes, the use of first generation DES, and increased MMP-2 levels were significant predictors of ISR with clinical presentation of ACS. In contrast, the use of aspirin, clopidogrel, high-dose statin, and ACE inhibitor prevented ISR with clinical presentation of ACS.
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Incidence and Clinical Impact of Stent Fracture After the Nobori Biolimus-Eluting Stent Implantation Background: Stent fracture (SF) after drug-eluting stent implantation has recently became an important concern. However, the incidence and clinical impact of SF after the Nobori biolimus-eluting stent (BES) remains unclear. Methods: A total of 1031 patients with 1407 lesions undergoing BES implantation and follow-up angiography 6 to 9 months after index procedure were analyzed. SF was defined as complete or partial separation of the stent, as assessed by plain fluoroscopy, intravascular ultrasound, or optical coherence tomography during follow-up. We assessed the rate of SF and major adverse cardiac events (MACE), defined as cardiac death, myocardial infarction, stent thrombosis, and clinically driven target lesion revascularization (TLR) within 9 months. Results: SF was observed in 58 of 1407 lesions (4.1%) and 57 of 1031 patients (5.5%). Lesions with hinge motion (odd ratio [OR], 6.15; 95% confidence interval [CI], 3.40-11.46; p<0.001), tortuosity (OR, 3.12; 95% CI, 1.46-7.31; p¼0.003), or overlapping stents (OR, 2.66; 95% CI, 1.23-5.81; p¼0.013) were independent predictors of SF. The MACE rate within 9 months were significantly higher in the SF group than in the non-SF group (28.1% vs. 4.6%, p<0.001). The rate of TLR was significantly higher in the SF group than in the non-SF group (28.0% vs. 4.1%, p<0.001), whereas the rate of myocardial infarction and stent thrombosis were not different between the 2 groups (1.8% vs. 1.0%, p¼0.61; 1.8% vs. 0.9%, p¼0.53, respectively).
Background: Though percutaneous coronary intervention with the XIENCE VÒ everolimus-eluting stent (EES, Abbott Vascular, Santa Clara, CA) for native coronary artery disease has favorable results compared to first generation drug-eluting stents, outcomes with EES for the treatment of in-stent restenosis (ISR) are unknown. The objective of this study is to evaluate the safety and efficacy of XIENCE V for the treatment of ISR. Methods: XIENCE V USA is a prospective observational multicenter registry evaluating clinical outcomes in patients who received treatment with EES. In this study, we present the 1-year clinical outcomes in patients who received EES for the treatment of ISR and non-ISR in this registry. The primary outcome was the composite of target lesion failure (defined as cardiac death, target vessel myocardial infarction, or target lesion revascularization). Secondary outcomes were myocardial infarction, target lesion revascularization, and stent thrombosis. Results: In this registry 383 patients (64AE11 years old; 68.4% male) received revascularization for single-vessel ISR and 4832 patients (64AE11 years old; 69.0% male) received revascularization for non-ISR lesions. At 1 year, the rate of clinical adverse events (Table) was higher in the ISR group compared the non-ISR group, however, these differences ceased to exist when case-control matched patients in the non-ISR group were studied. Conclusions: The treatment of ISR with EES appears to be safe and efficacious at 1-year follow-up. Compared to the non-ISR group, the rate of target lesion failure was much higher indicating a higher risk profile of these patients. However, these differences ceased to exist with case controlled matching.
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The Impact of Atherogenic Background: Pathological studies have revealed atherosclerotic neointima (AN) after stent implantation. However, the risk factor of neoatherosclerosis and its impact on future clinical events remain unclear. Methods: From the Kobe university OCT database, 137 consecutive patients (253 stents) who underwent OCT examination at >1 year after bare metal or first-generation drug-eluting stent implantation were enrolled. We assessed AN (neointima containing a diffuse border, signal-poor region with invisible struts underneath) by follow-up OCT and compared major adverse cardiovascular event (MACE: death, recurrent myocardial infarction and target lesion revascularization (TLR)) rate between +AN and -AN group. Results: 38 patients had AN at follow-up OCT, who had higher LDL-cholesterol and high sensitivity CRP (hs-CRP) level. In multivariate logistic analysis, LDL cholesterol and hs-CRP were the independent predictors of the presence of AN (OR 1.025 (P¼0.011), OR 1.016 (P¼0.045), respectively). The rate of MACE were significantly higher in +AN than in -AN for an average follow-up of 58 months after stenting. After multivariate cox hazard analysis, the presence of AN remained an independent risk factor of MACE (HR 2.345, 95% CI 1.010-5.440, P¼0.047).
Conclusions: Increased LDL-cholesterol and hs-CRP level may be risk factors for AN progression in patients treated with coronary stents. In this study, the presence of AN assessed by OCT were independently associated with MACE at >1 year after stent placement, suggesting a need for careful clinical follow-up of patients with AN.
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Is Background: The clinical presentation of bare metal in-stent restenosis (ISR) is reported to be associated with high rates of morbidity, including myocardial infarction (MI). This study aimed to compare the clinical presentation and outcomes between patients treated with 1st-versus 2nd-generation drug-eluting stents (DES) and presented with ISR on admission. Methods: The study identified first episode 1st or 2nd-generation DES ISR patients who underwent re-intervention. The clinical presentation at admission was classified as non acute (asymptomatic or stable angina) or acute (unstable angina, Canadian Cardiovascular Society (CCS) III or IV and MI). We compared the 1st-vs. 2nd-gen DES ISR clinical presentation and the rates of major adverse cardiac events (MACE) as a composite of death, Q-wave MI and target lesion revascularization at 6 months. Results: Overall, 709 patients with 1095 DES ISR lesions (1st-gen DES n¼526; 2ndgen DES n¼113) were selected. The mean age was 65 AE 10 years and diabetics comprised 49%. Clinical presentation included asymptomatic/stable angina in 29%, unstable angina in 62% and MI in 8%. Patients with 2nd-generation DES ISR were less likely to present as MI(13% vs. 5%; p¼0.05) and with severe symptoms (73% vs. 49%, p<0.01) as compared to 1st-gen DES. The incidence of MACE in the 1st-and 2nd-gen DES at 6 months was 8% and 9%, respectively (p¼1.0). Conclusions: 2nd-generation DES ISR clinical presentation appears to be more benign with less frequency of MI and CCS III or IV symptoms compared to 1stgeneration DES. The rates of MACE were similar at 6 months.
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Angiographic localized haziness after drug-coated balloon angioplasty in de-novo lesions does not increase the risk of acute coronary thrombosis Theresa Weichert 1 , Annette Fengler 1 , Philip Steen 1 , Klaus Bonaventura 1 1
Klinikum Ernst von Bergmann, Potsdam, Germany
Background: Clinical studies demonstrated the effectiveness and safety of drug-coated balloon (DCB) in various clinical scenarios and support the use of paclitaxel-coated balloon for the treatment of in-stent restenosis, of small coronary arteries and bifurcation lesions. A few small scale studies have reported excellent immediate and short term results of DCB use compared to non-coated balloon for de-novo lesions. Initial angiographic 
